Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection

Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: A 1-week, randomized, open-label study in chinese adults

(2010) Xiaolin Pan et al.   CLINICAL THERAPEUTICS

Rabeprazole Can Overcome the Impact of CYP2C19 Polymorphism on Quadruple Therapy

(2010) Chao-Hung Kuo et al.   HELICOBACTER

The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people

(2010) L. Zhang et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects

(2010) V. W. Y. Lee et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Rabeprazole

(2009) Claudine M. Baldwin et al.   DRUGS

Guide to the Use of Proton Pump Inhibitors in Adult Patients

(2008) Vandana Boparai et al.   DRUGS

Esomeprazole

(2008) Kate McKeage et al.   DRUGS

Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH

(2008) Julia Kirchheiner et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Effect of the CYP2C19 polymorphism on the eradication rate ofHelicobacter pyloriinfection by 7-day triple therapy with regular proton pump inhibitor dosage

(2008) Jung Mook Kang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY